SCHEMBL1543366

SCHEMBL1543366

O=C(O)N(Cc1ccccc1)C1CCCC(CO)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 3/20 0.48
MTNR1A P48039 1/20 0.48
CTSD P07339 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM3 P20309 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
OPRM1 P35372 4/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MC4R P32245 1/20 0.40
MC5R P33032 1/20 0.40
MC3R P41968 1/20 0.40
PKM P14618 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
MAPK1 P28482 1/20 0.40
CCR5 P51681 1/20 0.39
KCNH2 Q12809 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543369 1.00 AGER (0.48) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL1543364 1.00 AGER (0.48) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL13275874 0.88 CTSD (0.48) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL13275876 0.88 CTSD (0.48) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL5436734 0.88 AGER (0.55) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL5431901 0.88 AGER (0.55) AGERMTNR1ACTSDCHRM2CHRM3
SCHEMBL1543202 0.83 SLC6A2 (0.42) AGERMTNR1AOPRM1MEN1KMT2A
SCHEMBL1543200 0.83 SLC6A2 (0.42) AGERMTNR1AOPRM1MEN1KMT2A
SCHEMBL1543203 0.83 SLC6A2 (0.42) AGERMTNR1AOPRM1MEN1KMT2A
SCHEMBL17157336 0.82 AGER (0.50) AGERMTNR1ACTSDCHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307377-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173888-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 AGER 1552/4885MTNR1A 259/4885CTSD 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.